424B3: Prospectus

424B3：募資說明書

美股SEC公告 · 2024/09/10 07:28

Moomoo AI 已提取核心訊息

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has announced a prospectus for the potential offering of up to $100 million in mixed securities, which may include common stock, preferred stock, debt securities, warrants, purchase contracts, units, and subscription rights. The securities may be offered in various combinations and in one or more offerings. The securities may be convertible, exercisable, or exchangeable for other securities, and the offerings may be conducted through underwriters, dealers, agents, or directly to purchasers. The company has conducted reverse-stock-splits on December 4, 2023, and April 25, 2024, with ratios of 1-for-35 and 1-for-10, respectively, and all share and price information has been adjusted accordingly. The company's common stock is listed on The Nasdaq Stock Market LLC under the symbol 'ZVSA.' As of August 30, 2024, the last reported sale price of ZyVersa's common stock was $2.77 per share. The company has not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus. The date of the prospectus is September 9, 2024.

世界細胞治療公司ZyVersa Therapeutics宣佈擬通過發行最高100,000,000美元的混合證券的招股書，其中可能包括普通股、優先股、債務證券、認股權證、認購合同、單位和認購權。這些證券可以以不同的組合和多個發行方式發行。這些證券可以轉換、行使或兌換成其他證券，發行可以通過承銷商、經銷商、代理人或直接銷售給購買者。公司在2023年12月4日和2024年4月25日進行了逆向股票拆分，比例分別爲1股換35股和1股換10股，所有的股份和價格信息都相應進行了調整。公司的普通股在納斯達克證券交易所以「ZVSA」爲符號上市。截至2024年8月30日，ZyVersa的普通股最後報道的交易價爲每股2.77美元。公司在本招股書之前的12個日曆月內，未根據S-3條例第I.b.6條的一般指令發行任何證券。招股書的日期爲2024年9月9日。

有用

沒用

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

424B3: Prospectus

424B3: Prospectus

Moomoo AI 已提取核心訊息

風險及免責聲明

聲明